Cat. Number:

Anti-SARS Nucleocapsid Protein抗體KL-17237R

Quantity size:

0.2ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

Severe Acute Respiratory Syndrome (SARS), an emerging disease characterized by atypical pneumonia, has recently been attributed to a Anti-SARS Nucleocapsid Protein抗體novel coronavirus (SARS-CoV). SARS is caused by a human coronavirus, which are the major cause of upper respiratory tract illness in humans, such as the common cold. Coronaviruses are positive stranded RNA viruses, featuring the largest viral RNA genomes known to date (27-31 kb). The spike protein is the main surface antigen of the coronavirus. The most prominent protein in the culture supernatants infected with SARS virus is a 46 kDa nucleocapsid protein. This suggests that the nucleocapsid protein is a major immunogen that may be useful for early diagnostics. The nucleocapsid protein of SARS shares little homology with nucleocapsid proteins of other members of the coronavirus family. Nucleocapsid proteins of other coronavirus have been reported to be involved in forming the viral core and also in the packaging and transcription of the viral RNA.

Also known as:

N; N structural protein; NC; Nucleocapsid Anti-SARS Nucleocapsid Protein抗體protein; Nucleoprotein; Protein N; SARS coronavirus N protein; SARS CoV; SARSCoV; Severe acute respiratory syndrome.

Specificity:

Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500   
Not yet tested in other applications. Anti-SARS Nucleocapsid Protein抗體
Optimal working dilutions must be determined by the end user.